CYP2D6 and juvenile Huntington disease: Tetrabenazine is approved to treat Huntington's disease (HD) and is primarily metabolized by CYP2D6. Due to safety concerns caused by high exposure, patients with low activity of CYP2D6 should be treated with lower doses compared with extensive and intermediate metabolizers.